147 related articles for article (PubMed ID: 31758664)
21. Advances in the Pharmacogenomics of Antiplatelet Therapy.
Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N
Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.
Ratner L; Zhu J'; Gower MN; Patel T; Miller JA; Cipriani A; Stouffer GA; Crona DJ; Lee CR
Pharmacogenomics; 2022 Feb; 23(3):183-194. PubMed ID: 35083934
[No Abstract] [Full Text] [Related]
23. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Klein MD; Williams AK; Lee CR; Stouffer GA
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
[TBL] [Abstract][Full Text] [Related]
24. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
25. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
27. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
Bergmeijer TO; Vos GJ; Claassens DM; Janssen PW; Harms R; der Heide RV; Asselbergs FW; Ten Berg JM; Deneer VH
Pharmacogenomics; 2018 May; 19(7):621-628. PubMed ID: 29701129
[TBL] [Abstract][Full Text] [Related]
28. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
Hicks JK; El Rouby N; Ong HH; Schildcrout JS; Ramsey LB; Shi Y; Anne Tang L; Aquilante CL; Beitelshees AL; Blake KV; Cimino JJ; Davis BH; Empey PE; Kao DP; Lemkin DL; Limdi NA; P Lipori G; Rosenman MB; Skaar TC; Teal E; Tuteja S; Wiley LK; Williams H; Winterstein AG; Van Driest SL; Cavallari LH; Peterson JF;
Clin Pharmacol Ther; 2021 Jul; 110(1):179-188. PubMed ID: 33428770
[TBL] [Abstract][Full Text] [Related]
29. Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention.
Ramesh S; Socrates S; Rajasekaran MA; Senguttuvan N
Indian Heart J; 2020; 72(6):589-592. PubMed ID: 33357650
[TBL] [Abstract][Full Text] [Related]
30. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
31. International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.
Pereira NL; So D; Bae JH; Chavez I; Jeong MH; Kim SW; Madan M; Graham J; O'Cochlain F; Pauley N; Lennon RJ; Bailey K; Hasan A; Baudhuin LM; Bell MR; Lerman A; Goodman S; Mathew V; Farkouh M; Rihal CS
Pharmacogenet Genomics; 2019 Jun; 29(4):76-83. PubMed ID: 30724853
[TBL] [Abstract][Full Text] [Related]
32. Genotype-Guided Strategy for P2Y
Kheiri B; Simpson TF; Osman M; Kumar K; Przybylowicz R; Merrill M; Golwala H; Rahmouni H; Cigarroa JE; Zahr F
JACC Cardiovasc Interv; 2020 Mar; 13(5):659-661. PubMed ID: 32139230
[No Abstract] [Full Text] [Related]
33. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
[TBL] [Abstract][Full Text] [Related]
35. A Genotype-Guided Strategy for Oral P2Y
Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
[TBL] [Abstract][Full Text] [Related]
36. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Jiang M; You JH
Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
Klein MD; Lee CR; Stouffer GA
Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.
Kimpton JE; Carey IM; Threapleton CJD; Robinson A; Harris T; Cook DG; DeWilde S; Baker EH
Br J Clin Pharmacol; 2019 Dec; 85(12):2734-2746. PubMed ID: 31454087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
